Expertise in
2
conditions

Enrico N. De Toni

Munich, BY, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
2
conditions
Munich, BY, DE 

Overview

Enrico De Toni practices practicing medicine in Munich, Germany.

Mr. De Toni is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Liver Cancer, Cirrhosis, Cerebral Hypoxia, Liver Transplant, and Colonoscopy.

He is actively involved in clinical research, co-authoring 127 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Munich, BY, Germany
Other Locations
BY, Germany
Erlangen, BY, Germany
Heidelberg, BW, Germany
Maximilian, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, 2-arm Non-comparative Phase II Study on the Efficacy of Atezolizumab and Roche Bevacizumab (Atezo/Bev) Followed by On-demand Selective TACE (sdTACE) Upon Detection of Disease Progression or of Initial Synchronous Treatment With TACE and Atezo/Bev on 24-months Survival Rate in the Treatment of Unresectable Hepatocellular Carcinoma Patients
A Randomized, 2-arm Non-comparative Phase II Study on the Efficacy of Atezolizumab and Roche Bevacizumab (Atezo/Bev) Followed by On-demand Selective TACE (sdTACE) Upon Detection of Disease Progression or of Initial Synchronous Treatment With TACE and Atezo/Bev on 24-months Survival Rate in the Treatment of Unresectable Hepatocellular Carcinoma Patients
Enrollment Status: Recruiting
Publish Date: June 14, 2024
Intervention Type: Combination product
Study Drug: Atezolizumab Injection, Bevacizumab Injection
Study Phase: Phase 2

127 Total Publications

Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study.
Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 28, 2026

Frequently Asked Questions about Enrico N. De Toni

Is Enrico N. De Toni a top-rated expert for Liver Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Enrico N. De Toni is classified as an Elite expert for Liver Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Enrico N. De Toni participate in research or clinical trials?

Yes. Enrico N. De Toni has published 127 articles and abstracts on conditions like Liver Cancer. You can view a list of Enrico N. De Toni's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. De Toni's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile